Q2
ADPT — Q2 2026 Financial Report Analysis
Adaptive Biotechnologies grew Q2 2026 revenue 22% to $71.6M on 43% higher clonoSEQ test volume, but a $23.7M non-cash charge from paying off its OrbiMed financing widened the net loss to $39.8M ($0.25 per share).